PE20010579A1 - MESOPROGESTINES (PROGESTERONE RECEPTOR MODULARS) AS COMPONENTS OF FEMALE CONTRACEPTIVES - Google Patents

MESOPROGESTINES (PROGESTERONE RECEPTOR MODULARS) AS COMPONENTS OF FEMALE CONTRACEPTIVES

Info

Publication number
PE20010579A1
PE20010579A1 PE2000000894A PE0008942000A PE20010579A1 PE 20010579 A1 PE20010579 A1 PE 20010579A1 PE 2000000894 A PE2000000894 A PE 2000000894A PE 0008942000 A PE0008942000 A PE 0008942000A PE 20010579 A1 PE20010579 A1 PE 20010579A1
Authority
PE
Peru
Prior art keywords
mesoprogestines
modulars
components
progesterone receptor
female contraceptives
Prior art date
Application number
PE2000000894A
Other languages
Spanish (es)
Inventor
Walter Elger
Kristof Chwalisz
Gerd Schubert
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20010579A1 publication Critical patent/PE20010579A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE AL USO DE MESOPROGESTINAS DE 1 mg A 25mg, TAMBIEN SE REFIERE AL USO CON UN ESTROGENO COMO ETINILESTRADIOL, UTILIZANDOSE 10µg A 30µg, ESTRADIOL, ESTER ESTRADIOL, 3-SULFAMATO DE 17ß-ETINILESTRADIOL, 17ß-ESTRADIOL. LA COMPOSICION SE FORMULA PARA LA ADMINISTRACION ORAL O COMO SISTEMA INTRAUTERINO ANTICONCEPTIVO FEMENINO PARA PROVOCAR Y MANTENER LA AMENORREAIT REFERS TO THE USE OF MESOPROGESTINES FROM 1mg TO 25mg, ALSO REFERS TO THE USE WITH A ESTROGEN SUCH AS ETHINYLESTRADIOL, USING 10µg TO 30µg, ESTRADIOL, ESTER ESTRADIOL, 17ß-ETHINYLESTRADIOL 3-SULFAMATE, 17ß-ETHINYLESTRADIOL, 17ß-ESTRADIOL. THE COMPOSITION IS FORMULATED FOR ORAL ADMINISTRATION OR AS A FEMALE INTRAUTERINE CONTRACEPTIVE SYSTEM TO CAUSE AND MAINTAIN AMENORRHEA

PE2000000894A 1999-08-31 2000-08-31 MESOPROGESTINES (PROGESTERONE RECEPTOR MODULARS) AS COMPONENTS OF FEMALE CONTRACEPTIVES PE20010579A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38613399A 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
PE20010579A1 true PE20010579A1 (en) 2001-06-04

Family

ID=23524305

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000894A PE20010579A1 (en) 1999-08-31 2000-08-31 MESOPROGESTINES (PROGESTERONE RECEPTOR MODULARS) AS COMPONENTS OF FEMALE CONTRACEPTIVES

Country Status (28)

Country Link
EP (1) EP1605949A2 (en)
JP (1) JP2003511399A (en)
KR (1) KR20020038745A (en)
CN (1) CN1384748A (en)
AR (1) AR025455A1 (en)
AU (1) AU781835B2 (en)
BG (1) BG106441A (en)
BR (1) BR0013711A (en)
CA (1) CA2383650A1 (en)
CO (1) CO5190694A1 (en)
CZ (1) CZ2002707A3 (en)
EA (1) EA006805B1 (en)
EE (1) EE200200103A (en)
HR (1) HRP20020265A2 (en)
HU (1) HUP0202515A3 (en)
IL (1) IL148415A0 (en)
LT (1) LT5001B (en)
LV (1) LV12940B (en)
MX (1) MXPA02002186A (en)
NO (1) NO20020998L (en)
NZ (1) NZ517470A (en)
PE (1) PE20010579A1 (en)
PL (1) PL353994A1 (en)
SI (1) SI20853A (en)
SK (1) SK2982002A3 (en)
UA (1) UA77150C2 (en)
WO (1) WO2001026603A2 (en)
YU (1) YU13902A (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1525215T3 (en) * 2002-08-02 2007-01-15 Schering Ag Modulators for the progesterone receptor with elevated anti-gonadotropic activity for women's fertility control and hormone replacement therapy
DE10236405A1 (en) 2002-08-02 2004-02-19 Schering Ag New 4-(3-oxo-estra-4,9-dien-11 beta-yl)-benzaldehyde oximes, are progesterone receptor modulators useful in female contraception, hormone replacement therapy and treatment of gynecological disorders
US7772219B2 (en) * 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US20050215535A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
BRPI0512991A (en) * 2004-07-07 2008-04-22 Wyeth Corp use of a progestin, pharmaceutically useful kit adapted for daily oral administration, and method of contraception in a female of childbirth
DE102005050729A1 (en) * 2005-10-19 2007-04-26 Schering Ag Method of preventive on-demand hormonal contraception
NZ615430A (en) * 2009-04-14 2014-06-27 Laboratoire Hra-Pharma Method for on-demand contraception
CN110548034A (en) * 2019-07-12 2019-12-10 广州莎蔓生物科技有限公司 Pregnancy-blocking medicine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2054271A (en) 1932-05-17 1936-09-15 Schering Kahlbaum Ag Production of crystallized hormone esters
DE699310C (en) 1936-11-20 1940-11-27 Chemische Ind Ges Process for the preparation of compounds of the estradiol type which are esterified in the 3-position
US2225419A (en) 1937-03-01 1940-12-17 Schering Corp Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols
US2611773A (en) 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US2990414A (en) 1957-03-26 1961-06-27 Syntex Sa 17-undecenoate of estradiol
DE3337450A1 (en) 1983-10-12 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen PROSTAGLANDINE AND ANTIGESTAGE FOR PREGNANCY ABORT
HU214598B (en) * 1987-09-24 1998-04-28 Jencap Research Ltd Process for producing contraceptive compositions containing estragen and progestin and applicable for hormonal therapy
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5516769A (en) 1993-02-19 1996-05-14 The Medical College Of Hampton Roads Method of inhibiting fertilization
DE4332284C2 (en) * 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxime-17beta-methoxy-17alpha-methoxymethyl-estradiene derivatives, process for their preparation and medicaments containing these compounds
DE4332283A1 (en) * 1993-09-20 1995-04-13 Jenapharm Gmbh Novel 11-benzaldoximestradiene derivatives, processes for their preparation and medicaments containing these compounds
DE4429397C2 (en) 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5 (10) -triene derivatives, processes for their preparation and pharmaceutical compositions containing these compounds
DE4447715C2 (en) 1994-08-09 1998-02-05 Jenapharm Gmbh Oestrogen compsn contg. 3-sulphamoyl:oxy-oestratriene cpd.
ZA959008B (en) * 1994-10-24 1996-09-16 Schering Ag Competitive progesterone antagonists for demand-oriented female birth control
US6040340A (en) * 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
JP2000514785A (en) * 1996-06-25 2000-11-07 アクゾ・ノベル・エヌ・ベー Progestogen-anti-progestogen prescription
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (en) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituted 11beta-benzaldoxime-estra-4,9-diene-carbonic acid thiol esters, processes for their preparation and pharmaceutical preparations containing these compounds
EP1175422A2 (en) * 1999-05-04 2002-01-30 Ligand Pharmaceuticals Incorporated Tetracyclic progesterone receptor modulator compounds and methods

Also Published As

Publication number Publication date
PL353994A1 (en) 2003-12-15
HUP0202515A2 (en) 2002-12-28
EP1605949A2 (en) 2005-12-21
SI20853A (en) 2002-10-31
MXPA02002186A (en) 2002-09-02
WO2001026603A2 (en) 2001-04-19
BR0013711A (en) 2002-05-07
YU13902A (en) 2006-01-16
SK2982002A3 (en) 2002-07-02
CO5190694A1 (en) 2002-08-29
HUP0202515A3 (en) 2004-06-28
KR20020038745A (en) 2002-05-23
NO20020998L (en) 2002-03-14
NZ517470A (en) 2004-03-26
LT2002035A (en) 2002-10-25
EA200200284A1 (en) 2002-10-31
LT5001B (en) 2003-03-25
JP2003511399A (en) 2003-03-25
EA006805B1 (en) 2006-04-28
CZ2002707A3 (en) 2002-11-13
UA77150C2 (en) 2006-11-15
HRP20020265A2 (en) 2004-02-29
AR025455A1 (en) 2002-11-27
EE200200103A (en) 2003-04-15
CA2383650A1 (en) 2001-04-19
NO20020998D0 (en) 2002-02-28
AU781835B2 (en) 2005-06-16
AU3215001A (en) 2001-04-23
WO2001026603A3 (en) 2002-01-17
BG106441A (en) 2002-09-30
LV12940B (en) 2003-06-20
IL148415A0 (en) 2002-09-12
CN1384748A (en) 2002-12-11

Similar Documents

Publication Publication Date Title
CY1108093T1 (en) MEDICINAL DELIVERY SYSTEM CONSISTING OF tetrahydroxylated estrogen for use in hormonal contraception
KR970706001A (en) PROCESS OF MAKING DOSAGE UNITS BY WET GRANULATION BY WET-GRANULATION
BRPI0512991A (en) use of a progestin, pharmaceutically useful kit adapted for daily oral administration, and method of contraception in a female of childbirth
AR011480A1 (en) ACIL-ANILIDS SUBSTITUTED WITH CYCLICAL RADICALS (HETERO), NON-STEROIDAL, WITH GESTÁGENA AND MIXED ANDROGENA ACTIVITY.
RS50972B (en) Pharmaceutical composition containing gestagens and/or estrogens and 5-methyl-(6s)-tetrahydrofolate
TW200605880A (en) Progesterone receptor antagonist contraceptive regimens and kits
AU560487B2 (en) Contraceptive comprising gestodene and ethinylestradiol
ECSP055629A (en) COMPOSITION CONTAINING AN ANDROGEN 11ß-HALOGENATED STEROID AND A GESTAGEN AS WELL AS A MALE CONTRACEPTIVE ON THE BASIS OF THESE COMPOSITIONS
PE20060127A1 (en) DRUG DELIVERY SYSTEM CONSISTING OF POLYETHYLENE COPOLYMER VINYL ACETATE
AP9801384A0 (en) Improvements of implantation rates after in vitro fertilization.
CY1105276T1 (en) TRIPHASIC ORAL CONTRACEPTIVE
BR0116793A (en) Steroid Hormone Products and Methods for Preparing Them
ECSP084358A (en) NEW SOLID FORMS OF MESOPROGESTINE 11ß- [4E- (HYDROXYIMINOMETIL) -PENYL] - 17ALFA-METOXIMETIL-17ß-METOXI-ESTRA-4,9-DIEN-3-ONA
DE122007000011I1 (en) Solid dosage forms containing clathrates of the steroidal sex hormone ethinyl estradiol
PT868188E (en) KIT FOR CONTRACEPTION IN FEMALE MAMMALS CONTAINING A COMBINATION OF GESTAGEN AND ESTROGEN
ES2114605T3 (en) CONTRACEPTIVE METHOD USING A COMPETITIVE PROGESTERONE ANTAGONIST AND NEW COMPOUNDS USED IN IT.
CR7611A (en) USE OF CILOTIOCARBAMATE DERIVATIVES IN TREATMENT OF CONDITIONS RELATED TO HORMONE
PE20010579A1 (en) MESOPROGESTINES (PROGESTERONE RECEPTOR MODULARS) AS COMPONENTS OF FEMALE CONTRACEPTIVES
CO5631449A2 (en) NEW ETONOGESTREL ESTERS
BR9911344A (en) Compound, ment undecanoate, use of it, pharmaceutical formulation, and, kit for male contraception.
IT1154735B (en) AMINO-14 STEROID DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION
Hahn et al. The pharmacological profile of norgestimate, a new orally active progestin
CU23414B7 (en) STRATRIENS 9-ALPHA-SUBSTITUTED AS SELECTIVE EFFECTIVENESS STRATEGES
Nutting et al. Anabolic-androgenic activity of A-ring modified androstane derivatives. Part I: A comparison of parenteral activity
PE20010581A1 (en) MESOPROGESTINES (MODULAR PROGESTERONE RECEPTORS) AS COMPONENTS OF COMPOSITIONS USED FOR HORMONE SUBSTITUTION THERAPY (HRT)

Legal Events

Date Code Title Description
FC Refusal